Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia

Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)

Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Niagen Bioscience initiated with a Buy at Freedom Broker

Niagen Bioscience Shareholders Back Board and Governance Measures

Niagen Bioscience Holds Annual Shareholder Meeting, Elects Directors

Niagen Bioscience - up to $50 Mln of Common Stock May be Sold Under Sales Agreement Dated June 26, 2026 - SEC Filing

Niagen Bioscience - May Offer up to $125 Mln of Securities - SEC Filing

Niagen Bioscience to present at East Coast IDEAS Investor Conference

Niagen Bioscience renames CERP to Niagen Research Program

Niagen Bioscience Rebrands External Research Program to Strengthen NAD+ Scientific Leadership

Analysts Are Bullish on Top Healthcare Stocks: Niagen Bioscience (NAGE), Guardant Health (GH)

BRIEF-NARB Recommends Niagen Modify/Discontinue Certain Tru Niagen Nad+ Dietary Supplement Claims

National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen Nad+ Dietary Supplement Claims

Niagen Bioscience Earnings Call Highlights Growth Push